一、中文部分
(一) 書籍
1. 王火燦,《WTO與知識產權爭端》,WTO案例叢書,上海人民出版社(2001年)。
2. 邱宏達,《現代國際法》,三民書局(1995年)。
3. 洪德欽,《WTO法律與政策專題研究》,學林文化事業有限公司,民國91年,頁13。
4. 陳文吟,《我國專利制度之研究》,五南圖書出版公司(1995年)。
5. 陳治世,《國際法》,台灣商務印書館(1990年)。
6. 陳洁越倩編,《WTO與知識產權法律實務》,WTO法律實務論叢,吉林人民出版社(2001年)。
7. 陳哲宏、陳逸南、謝銘洋、徐宏昇,《專利法解讀》,元照出版公司(2000年)。
8. 陳隆志,《當代國際法引論》,元照出版公司(1999年)。
9. 黃立、李貴英、林彩瑜,《WTO國際貿易法論》,元照出版公司(2003年)。
10. 蔡明誠,《發明專利法研究》,國立台灣大學法學叢書,國立台灣大學法學院(1998年)。
11. 鄭成思,《WTO知識產權協議逐條講解》,中國方正出版社(2001年)。
12. 謝銘洋,《智慧財產權之制度與實務》,國立台灣大學法學叢書,翰蘆圖書公司(1995年)。
13. 謝銘洋,《智慧財產權之基本問題研究》,國立台灣大學法學叢書,翰蘆圖書公司(2002年)。
14. 謝銘洋,《智慧財產權之基礎理論》,國立台灣大學法學叢書,翰蘆圖書公司(2001年)。
15. 羅昌發,《國際貿易法》,元照出版公司(1999年)。
(二) 期刊論文
1. Cornish, W. R.、吳必然譯,〈智慧財產權保護之適當範圍:以平行輸入為例〉,《競爭政策通訊》,第3卷第2期,民國88年,頁48-55。
2. 王睦齡,〈我國專利法上之平行輸入與耗盡原則的探討〉,《法令月刊》,第53卷第6期,民國91年,頁33-44。3. 王睦齡,〈美國專利平行輸入與耗盡原則之探討〉,《智慧財產權》,第41期,民國91年,頁14-31。
4. 余翔,〈專利權之耗盡與專利品之平行輸入―歐體法律、實踐及相關理論剖析〉,《月旦法學雜誌》,第64期,民國89年,頁115-127。5. 李幸懋、徐宏昇,〈日本最高法院『學名藥』(Generic Drug)判決評論〉,1999全國智慧財產權研討會論文集,交通大學,民國88年。
6. 李忠雄,〈WTO架構下智慧財產權之保護〉,《全國律師》,第6卷第3期,民國91年3月,頁38-47。7. 李淑明,〈淺談我國專利制度未來發展方向--以TRIPs協定為中心〉,《智慧財產》,第19期,民國85年9月,頁61-79。8. 李森堙,〈從WTO「TRIPS協定與公眾健康宣言」談藥物專利與強制授權〉,《智慧財產權管理》,第32期, 民國91年3月,頁12-16。
9. 林彩瑜,〈Trade and Intellectual Property―A GATT/WTO Connection〉,《進口救濟論叢》,第14期,民國88年,頁1-24。10. 林彩瑜,〈WTO TRIPS協定下醫藥專利與公共健康之問題及其解決方向〉,《WTO、科技與環境學術研討會論文集》,民國92年4月。
11. 林彩瑜,〈開發中國家與WTO「特殊且差異之待遇」條款〉,《台大法學論叢》,第31卷第1期,民國90年3月。
12. 倪貴榮,〈WTO智慧財產權保護與公共健康議題之發展趨勢〉,《經社法治論叢》,行政院經濟建設委員會,第31期,民國92年1月,頁129-158。
13. 徐揮彥,〈與智慧財產權有關之貿易協定下有關藥品專利與健康權問題之研究〉,第三屆國際經貿法學發展學術研討會,政治大學,民國92年3月。
14. 張凱娜,〈專利物品平行輸入之探討―由歐盟相關案例的法律規範看我國廠商未來因應之道〉,《全國律師》,第3卷第1期,民國88年,頁5-15。15. 莊勝榮,〈平行輸入專利產品之研析〉,《法令月刊》,第46卷第4期,民國84年,頁14。16. 陳井星,〈論智慧財產權的概念―從WTO與貿易有關智慧財產權協定之觀點〉,《法令月刊》,第53卷第6期,民國91年,頁3-12。17. 陳文吟,〈探討因應醫藥品專利之合理措施〉,《國立中正大學法學集刊》,第8期,民國91年,頁67-112。18. 陳逸南,〈從TRIPS協定與公眾健康爭議論專利強制授權之功能與侷限〉,《2002全國科技研討會論文集》,交通大學科技法律研究所,民國91年。
19. 越宏,〈關於TRIPS協議與公共健康談判之思考―WTO的活動需要體現人類根本利益〉,《WTO經濟導刊》第2期,2003年3月,頁21-23。
20. 蔡明誠,〈加入WTO對我國智慧權保護法制的影響〉,《月旦法學雜誌》,第79期,民國90年12月,頁47-58。21. 蔡明誠,〈從WTO貿易智慧權協定觀點看國際智慧權保護標準之發展〉,《律師雜誌》,第243期, 民國88年12月,頁19-30。22. 蔡東廷,〈從WTO架構下之智慧財產權規範看我國專利制度之發展〉,《智慧財產權管理》,第33期,民國91年6月,頁10-15。23. 鄧衍森,〈從國際人權法論健康權之法理基礎與實踐方式〉,《東吳大學法律學報》,第11卷第1期,民國87年1月,頁55-72。
24. 謝銘洋,〈專利進口權與平行輸入〉,《月旦法學雜誌》,第2期,民國84年,頁80-86。25. 羅昌發,〈WTO 下之智慧財產權保護與貿易自由化之關係〉,《工業財產權與標準》,第25期,民國84年,頁1-21。二、外文部分
(一) 書籍
1. Correa, Carlos, Intellectual Property Rights, the WTO and Developing Countries, The TRIPS Agreement and Policy Options, (Zed Books, Third Word Network, 2000)
2. Carvalho, Nuno Pires, The TRIPS Regime of Patent Rights, (Kluwer Law International, 2002)
3. Gallagher, Peter, Guide to the WTO and Developing Countries, (Kluwer Law International, 2000)
4. Stewart, Terence, After Doha─the Changing Attitude & Ideas of the New WTO Round, (Transnational Publishers, 2002)
5. Watal, Jayashree, Intellectual Property Rights in the WTO and Developing Countries, (Kluwer Law International, 2001)
6. Toebes, Brigit, The Right to Health as a Human Right in International Law, (Intersentia Antwerpen — Groningen - Oxford, 1999)
7. Trebilcock, Michael and Howse, Robert, The Regulation of International Trade, 2nd ed., (Routledge, 1999)
(二) 期刊論文
1. Abbot, Frederic, “First report (final) to the Committee on International Trade Law of the International Law Association on the subject of parallel importation,” Journal of International Economic Law 607-636 (Winter 1998), Oxford University Press.
2. Abbott, Frederic, “Compulsory Licensing for Public Health Needs. The TRIPS Agenda at the WTO after the Doha Declaration on Public Health,” Occasional Paper 9. Geneva, Quaker United Nations Office, 2002.
3. Abbott, Frederic, “The Doha Declaration on the TRIPS Agreement and Public Health: Lighting a Dark Corner at the WTO,” 5(2) Journal of International Economic Law 469-505 (Jun. 2002), Oxford University Press.
4. Abbott, Frederic, “The TRIPS Agreement, Access to Medicines and the WTO Doha Ministerial Conference,” Occasional Paper 7. Geneva, Quaker United Nations Office, 2001.
5. Abbott, Frederick, “WTO TRIPS Agreement and Its Implications for Access to Medicines in Developing Countries,” Study Paper 2a, UK Commission on Intellectual Property Rights.
http://www.iprcommission.org/papers/pdfs/study_papers/sp2a_abbott_study.pdf (22/1/2003)
6. Attaran, Amir, “The Doha Declaration on the TRIPS Agreement and Public Health, Access to Pharmaceuticals, and Options under WTO Law,” Fordham Intellectual Property, Media & Entertainment Law Journal 859 (Spring 2002)
7. Avedissian, Grace, “Global Implication of a Potential U.S. Policy Shift toward Compulsory Licensing of Medical Inventions in a New era of “Super-Terrorism,” 18 American University International Law Review 237-294 (2002)
8. Bale, HE, “Patent protection and pharmaceutical innovation,” 29(1/2) New York University Journal of International Law and Politics 95-107 (1997)
9. Bale, HE, “The conflicts between parallel trade and product access and innovation: the case of pharmaceuticals,” Journal of International Economic Law 637-653 (Winter 1998), Oxford University Press.
10. Bass, Naomi, “Implications of the TRIPS Agreement for Developing Countries: Pharmaceutical Patent Laws in brazil and South Africa in the 21st Century,” George Washington International Law Review 191 (2002)
11. Berger, Jonathan, “THE GLOBAL AIDS CRISIS: Tripping Over Patents: AIDS, Access to Treatment and the Manufacturing of Scarcity,” Connecticut Journal of International Law 157 (Spring 2002)
12. Bloche, M, “Introduction: Health and the WTO,” 5(4) Journal of International Economic Law 821-824 (Dec. 2002), Oxford University Press.
13. Bloche, M, “WTO Deference to National Health Policy: Toward an Interpretive Principle,” 5(4) Journal of International Economic Law 825-848 (Dec. 2002), Oxford University Press.
14. Brown, Eric, “decisions of the Appellate Body of the World Trade Organization/ TRIPS: India─Patent Protection for Pharmaceutical and Agricultural Chemical Products,” Vol.9 No.1 European Journal of International Law (1998)
15. Champ, Paul and Attaran, Amir, “Patent Rights and Local Working under the WTO TRIPS Agreement: An Analysis of the U.S.-Brazil Patent Dispute,” The Yale Journal of International Law 365 (Summer 2002)
16. Chapman, Audrey, “The Human Rights Implications of Intellectual Property Protection,” 5(4) Journal of International Economic Law 861-882 (Dec. 2002), Oxford University Press.
17. Correa, Carlos, “Implementing the TRIPS Agreement in the patents field: options for developing countries,” 1(1) The Journal of World Intellectual Property 75-100 (1998)
18. Correa, Carlos, “Implications of the Doha Declaration on the TRIPS Agreement and Public Health,” Health Economics and Drugs. EDM Series No.12. WHO/EDM/PAR/2002.3
19. Correa, Carlos, “Recent Development in the Field of Pharmaceutical Patents: Implementation of the TRIPS Agreement,” Dec. 1998
http://www.haiweb.org/campaign/novseminar/correa2.html (22/1/2003)
20. Correa, Carlos, “TRIPS Disputes: Implications for the Pharmaceutical Sector,” Occasional Paper 5. Geneva, Quaker United Nations Office, 2001.
21. DiMasi, Joseph, Hansen, Ronald, and Grabowski, Henry, The price of Innovation: New Estimates of Drug development Costs, Boston MA: Tufts University Center for the study of Drug development 2002.
22. Ferreira, Lissett, “Access to Affordable HIV/AIDS Drugs: The Human Rights Obligations of Multinational Pharmaceutical corporations,” Fordham Law Review 1133 (Dec. 2002)
23. Ford, Sara, “Compulsory Licensing Provisions under the TRIPs Agreement: Balancing Pills and Patents,” American University International Law Review 941 (2000)
24. Garcia-Castrillon, Carmen Otero, “An Approach to the WTO Ministerial Declaration on the TRIPS Agreement and Public Health,” 5(1) Journal of International Economic Law 212-219 (March 2002)
25. Gathii, James, “Rights, Patents, Markets and the Global AIDS Pandemic” Florida Journal of International Law 261 (Spring 2002)
26. Gathii, James, “The Legal Status of the Doha Declaration on TRIPS and Public Health under the Vienna Convention on the Law of treaties,” Harvard Journal of Law & Technology 291 (Spring 2002)
27. Gollin, Michael. “Generic Drugs, Compulsory Licensing, and Other Intellectual Property Tools for Improving Access to Medicine,” Occasional Paper 3. Geneva, Quaker United Nations Office, 2001
28. Grabowski, Henry and Vernon, John, “Effective Patent Life in Pharmaceuticals,” 19 International Journal of Technology Management (2000) 98-120.
29. Grabowski, Henry, “Patents, Innovation and Access to New Pharmaceuticals,” 5(4) Journal of International Economic Law 849-860 (Dec. 2002), Oxford University Press.
30. Hammer, Peter, “Differential Pricing of Essential AIDS Drugs: Markets, Politics and Public Health,” 5(4) Journal of International Economic Law 883-912 (Dec. 2002), Oxford University Press.
31. Hepburn, Jonathan, “A Development Agenda for Implementing TRIPS: Addressing Biodiversity, Food, and Health Needs,” Quaker United Nations Office,
http://www.geneva.quno.info/pdf/final%20Jongny%204%20report.pdf (22/1/2003)
32. Hoen, Ellen, “TRIPs, Pharmaceutical Patents, and Access to Essential Medicines: A Long Way From Seattle to Doha,” 3(1) Chicago Journal of International Law 27-48 (Spring 2002)
33. Joni, Jennifer, “The Global AIDS Crisis: Access to Treatment for HIV/AIDS: A Human Rights Issue in the Developing World,” Connecticut Journal of International Law 273 (Spring 2002)
34. Keayla, B, “TRIPS Agreement on patent laws: impact on pharmaceuticals and health for all,” Paper presented at the International Conference on Global Health Laws, New Delhi, India, 5-7 (December 1997)
35. Keayla, B, “TRIPS Patent System: Core and Important Issues of Concern,” http://www.sisshyd.net/siss/docs/keayla.doc (22/1/2003)
36. Krause, Catarina, “The Right to Property,” Economic, Social, and Cultural Rights, 191-209 (Kluwer Law International 2001)
37. Lacayo, Amoldo, “Seeking a Balance: International Pharmaceutical Patent Protection, Public Health Crisis, and the Emerging Threat of Bio-Terrorism,” University of Miami Inter-American Law Reviews 295-320 (Summer/Fall 2002)
38. Lovett, William, “Reflections on the WTO Doha Ministerial: bargaining challenges and Conflicting Interests: Implementing the Doha Round,” American University International Law Review 951 (2002)
39. MacGeary, Johanna, “AIDS in Africa: the Specter of HIV,” TIME, 19 Feb. 2001.
40. Murthy, Divya, “The Future of Compulsory Licensing: Deciphering the Doha Declaration on the TRIPs Agreement and Public Health,” American University International Law Review 1299 (2002)
41. Nagan, Winston, “International Intellectual Property, Access to Health care, and Human Rights: South Africa v. United States,” Florida Journal of International Law 155 (Spring 2002)
42. Nogues, J, “Patents and Pharmaceutical Drugs: Understanding the Pressures on Developing Countries,” The Global Trading System Vol.3, 276-299 (London New York, 2002)
43. P, Drahos, Developing Countries and International Intellectual Property Standard-Setting, study prepared for the UK Commission on Intellectual Property Rights, 2002, available at http://www.iprcommission.org. (visited 5/4/2003)
44. Rozek RP, Tully N, “The TRIPS Agreement and access to health care,” 2(5) Journal of World Intellectual Property 813-819 (1999)
45. Scherer, F and watal, Jayashree, “Post-TRIPS Options for Access to Patented Medicines in Developing Nations,” 5(4) Journal of International Economic Law 913-940 (Dec. 2002), Oxford University Press.
46. Schott, Jeffery, “Comment on the Doha Ministerial,” 5(1) Journal of International Economic Law 191-195 (March 2002)
47. Sell, susan, “Proceedings of the 2002 Conference Access to Medicines in the Developing World: International Facilitation or Hindrance?: Panel #2: TRIPS and Access to Medicines: TRIPS and the Access to Medicines Campaign,” Wisconsin International Law Journal 481 (Summer 2002)
48. Shanker, Daya, “The Vienna Convention on the Law of Treaties, the Dispute settlement System of the WTO and the Doha Declaration on the TRIPs Agreement,” 36(4) Journal of World Trade 721-772 (Aug. 2002)
49. Sun, Haochen, “Reshaping the TRIPs agreement Concerning Public Health: Two Critical Issues,” 37 (1) Journal of world Trade 163-197 (April. 2003)
50. Sykes, Alan, “TRIPs, Pharmaceuticals, Developing Countries, and the Doha “Solution”,” 3(1) Chicago Journal of International Law 49-68 (Spring 2002)
51. Thomas, John, “HIV/AIDS drugs, Patents and the TRIPS Agreement: Issues and Options,” CRS Report for Congress (Jul 27, 2001)
http://rxpolicy.com/studies/crs-aidspatentstrips-0701.pdf (22/1/2003)
52. Toebes, Brigit, “The Right to Health,” Economic, Social, and Cultural Rights, 169-190 (Kluwer Law International 2001)
53. Torres, Mary, “Public Health and International Law: the Human Right to Health, National Courts, and Access to HIV/AIDS Treatment: A case Study from Venezuela,” Chicago Journal of International Law 105 (Spring 2002)
54. Williams, Mariama, “The TRIPS and Public Health Debate: An Overview,” International Gender and Trade Network, August 2001.
55. Wojahn, Patrick, “A Conflict of Rights: Intellectual Property under TRIPS, the Right to Health, and AIDS Drugs,” UCLA Journal of International Law 463 (Fall 2001)
56. WHO, “Globalization and Access to Drugs,” Health, Economics and Drugs, DAP Series No.7 (Revised), http://www.who.int/medicines/library/dap/who-dap-98-9-rev/who-dap-98-9rev.pdf (visited 22/1/2003)
57. WHO, “Globalization, patents and drugs─An annotated bibliography,”
http://www.who.int/medicines/organization/ood/trips_med.shtml (visited 22/1/2003)
58. WHO, “Globalization, TRIPS and access to pharmaceuticals,” No. 3 March 2001, WHO Policy Perspectives on Medicines, http://www.who.int/medicines/library/edm_general/6pagers/PPM03ENG.pdf (visited 22/1/2003)
59. Network for Monitoring the Impact of Globalization and TRIPS on Access to Medicines, Meeting Report, 19-21 Feb. 2001, Chulalongkorn University, Thailand.
60. Network for Monitoring the Impact of Globalization and TRIPS on Access to Medicines. Health Economics and Drugs. EDM Series No.11. WHO/EDM/PAR/2002.1.
61. WHO and WTO Secretariats, WTO Agreements and Public Health, 2002, http://www.wto.org/english/res_e/booksp_e/who_wto_e.pdf (visited 13/2/2003)
62. WHO and WTO Secretariat, “Report of the Workshop on Differential Pricing and Financing of Essential Drugs,” Norwegian Foreign Affairs Ministry, Global Health Council, 8-11 April 2001, Høsbjør, Norway http://www.who.int/medicines/library/edm_general/who-wto-hosbjor/wholereporthosbjo rworkshop-fin-eng.pdf (visited 22/1/2003)
63. Quaker United Nations Office, “Report on a Workshop on: The WTO TRIPS Agreement and the protection of Public Health: Implementing Paragraph 6 of the Doha Declaration,” Jul. 20-23 Norway, http://www.geneva.quno.info/pdf/final%20Utstein%20report.pdf (visited 22/1/2003)
64. “The TRIPS Agreement and Pharmaceuticals,” Report of an ASEAN Workshop, Jakarta, May 2-4, 2000, http://www.who.int/medicines/library/dap/aseantripsagreement.pdf (visited 22/1/2003)
65. TRIPS and Healthcare: Rethinking the Debate, International Policy Network (Jul. 2001) http://www.policynetwork.net/pdfs/rethinking_the_debate_0701.pdf (visited 22/1/2003)
66. WTO, “TRIPS and Pharmaceutical patents,” WTO Fact Sheet (Apr. 2001) http://www.wto.org/english/tratop_e/trips_e/tripsfactsheet_pharma.pdf (visited 22/1/2003)
67. United Nations, “Report of the High Commissioner of the Human Rights Commission on Economic, Social and Cultural Rights, The Impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights on Human Rights,” UN Doc E/CN.4/Sub.2/2001/13 (2001)
68. United Nations Economic and Social Council, “The Right to the Highest Attainable Standard of Health,” E/C. 12/2000/4, CESCR General Comment 14. (11/08/2000)
三、網站資料
1. www.trade.gov.tw (經濟部國際貿易局)
2. www.moeaipo.gov.tw (經濟部智慧財產局)
3. www.wto.org (World Trade Organization)
4. www.who.int (World Health Organization)
5. www.wipo.org (World Intellectual Property Organization)
6. www.oxfam.org (Oxfam International)
7. www.geneva.quno.info (Quaker United Nations Office)
8. www.unaids.org (UNAIDS)